AtriCure, Inc. (ATRC)
Stock Price:
$40.41 USD
-0.37 (-0.91%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.82B |
| Revenue (ttm) |
211.98M |
| Net Income (ttm) |
-50.10M |
| Shares Out |
44.93M |
| EPS (ttm) |
-1.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$40.41 |
| Previous Close |
$40.78 |
| Change ($) |
-0.37 |
| Change (%) |
-0.91% |
| Day's Open |
40.77 |
| Day's Range |
40.10 - 41.15 |
| Day's Volume |
227,656 |
| 52-Week Range |
22.57 - 51.76 |
More Stats
| Market Cap |
1.82B |
| Enterprise Value |
1.66B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.93M |
| Float |
43.54M |
| EPS (basic) |
-1.3 |
| EPS (diluted) |
-1.28 |
| FCF / Share |
-1.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.31M |
| Short Ratio |
4.74 |
| Short % of Float |
4.09% |
| Beta |
0.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.57 |
| PB Ratio |
4.40 |
| Revenue |
211.98M |
| Operating Income |
-46.70M |
| Net Income |
-50.10M |
| Free Cash Flow |
-44.39M |
| Net Cash |
157.69M |
| Net Cash / Share |
3.51 |
| Gross Margin |
80.35% |
| Operating Margin |
-22.03% |
| Profit Margin |
-23.60% |
| FCF Margin |
-20.94% |
| ROA |
-5.83% |
| ROE |
-15.22% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$55.62*
(37.64% upside)
Low
50.0
Current: $40.41
High
63.0
Target: 55.62
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 231 | 202 | 175 | 155 | 130 | 107 | 81.89 | 70.25 | 64.40 | 59.01 |
| Revenue Growth | 14.47% | 15.4% | 12.64% | 19.54% | 20.75% | 31.22% | 16.57% | 9.08% | 9.14% | - |
| Gross Profit | 170 | 147 | 126 | 111 | 92.88 | 75.75 | 59.56 | 50.01 | 47.00 | 45.39 |
| Operating Income | -33.12 | -17.13 | -24.98 | -31.14 | -26.72 | -16.36 | -10.89 | -7.20 | -4.73 | -3.19 |
| Net Income | -35.19 | -21.14 | -26.89 | -33.34 | -27.21 | -16.21 | -11.46 | -7.53 | -5.46 | -3.79 |
| Shares Outstanding | 37.59 | 34.09 | 32.39 | 31.61 | 28.06 | 26.37 | 20.43 | 16.19 | 15.67 | 15.10 |
| Earnings Per Share | -0.94 | -0.62 | -0.83 | -1.05 | -0.97 | -0.61 | -0.56 | -0.47 | -0.35 | -0.25 |
| Operating Cash Flow | -15.81 | -4.17 | -8.94 | -15.12 | -7.84 | -21.60 | -5.22 | -1.94 | -1.99 | -0.03 |
| Capital Expenditures | -12.14 | -6.21 | -6.38 | -7.69 | -24.00 | -9.13 | -2.82 | -2.96 | -1.13 | -1.81 |
| Free Cash Flow | -27.95 | -10.38 | -15.33 | -22.81 | -31.84 | -30.73 | -8.04 | -4.90 | -3.12 | -1.84 |
| Cash & Equivalents | 81.80 | 124 | 34.45 | 44.01 | 34.58 | 59.65 | 26.21 | 12.00 | 14.18 | 12.57 |
| Total Debt | 76.42 | 52.46 | 36.86 | 37.21 | 13.71 | 4.06 | 6.45 | 8.44 | 6.47 | 2.85 |
| Net Cash / Debt | 5.38 | 71.94 | -2.41 | 6.80 | 20.87 | 55.59 | 19.76 | 3.56 | 7.71 | 9.72 |
| Assets | 558 | 357 | 268 | 276 | 273 | 158 | 112 | 32.43 | 33.86 | 33.72 |
| Liabilities | 311 | 107 | 107 | 108 | 86.41 | 25.87 | 39.34 | 19.93 | 18.24 | 16.98 |
| Book Value | 247 | 249 | 161 | 168 | 187 | 133 | 72.60 | 12.50 | 15.62 | 16.74 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AtriCure, Inc. |
| Country |
United States |
| Employees |
730 |
| CEO |
Michael H. Carrel |
Stock Information
| Ticker Symbol |
ATRC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: ATRC |
| IPO Date |
August 5, 2005 |
Description
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.